Fig. 5

Prediction results of GInLncSig were superior to those of KRAS mutation status and existing lncRNA signatures. A-C The proportion of KRAS mutations in the high-risk group in the training set, test set, and TCGA set was significantly higher than that in the low-risk group (Chi-squared test, P < 0.05). D Co-survival analysis of GInLncSig and KRAS mutation status showed significant differences among the four groups (log-rank test, P < 0.001). E ROC curves for 1-year survival prediction of GInLncSig was better compared with the performance of the 3 previously reported lncRNA signatures